

Anti-Migraine Drugs-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/A126625ADE8EN.html

Date: December 2017

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: A126625ADE8EN

Abstracts

Report Summary

Anti-Migraine Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Migraine Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Anti-Migraine Drugs 2013-2017, and development forecast 2018-2023

Main market players of Anti-Migraine Drugs in Europe, with company and product introduction, position in the Anti-Migraine Drugs market

Market status and development trend of Anti-Migraine Drugs by types and applications Cost and profit status of Anti-Migraine Drugs, and marketing status Market growth drivers and challenges

The report segments the Europe Anti-Migraine Drugs market as:

Europe Anti-Migraine Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany
United Kingdom
France
Italy
Spain



Benelux

Russia

Europe Anti-Migraine Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Triptans

Ergots

Others

Europe Anti-Migraine Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Women

Men

Europe Anti-Migraine Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-Migraine Drugs Sales Volume, Revenue, Price and Gross Margin):

Eli Lilly

Abbott Laboratories

Eisai

Allergan

Endo

GlaxoSmithKline

Impax Laboratories

Pfizer

AstraZeneca

Bayer

Johnson & Johnson

Merck

Teva

Allergan

Amgen

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF ANTI-MIGRAINE DRUGS

- 1.1 Definition of Anti-Migraine Drugs in This Report
- 1.2 Commercial Types of Anti-Migraine Drugs
 - 1.2.1 Triptans
 - 1.2.2 Ergots
 - 1.2.3 Others
- 1.3 Downstream Application of Anti-Migraine Drugs
 - 1.3.1 Women
- 1.3.2 Men
- 1.4 Development History of Anti-Migraine Drugs
- 1.5 Market Status and Trend of Anti-Migraine Drugs 2013-2023
 - 1.5.1 Europe Anti-Migraine Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Anti-Migraine Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Anti-Migraine Drugs in Europe 2013-2017
- 2.2 Consumption Market of Anti-Migraine Drugs in Europe by Regions
 - 2.2.1 Consumption Volume of Anti-Migraine Drugs in Europe by Regions
 - 2.2.2 Revenue of Anti-Migraine Drugs in Europe by Regions
- 2.3 Market Analysis of Anti-Migraine Drugs in Europe by Regions
 - 2.3.1 Market Analysis of Anti-Migraine Drugs in Germany 2013-2017
 - 2.3.2 Market Analysis of Anti-Migraine Drugs in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Anti-Migraine Drugs in France 2013-2017
 - 2.3.4 Market Analysis of Anti-Migraine Drugs in Italy 2013-2017
 - 2.3.5 Market Analysis of Anti-Migraine Drugs in Spain 2013-2017
 - 2.3.6 Market Analysis of Anti-Migraine Drugs in Benelux 2013-2017
 - 2.3.7 Market Analysis of Anti-Migraine Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Anti-Migraine Drugs in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Anti-Migraine Drugs in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Anti-Migraine Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Europe Market Status by Types
 - 3.1.1 Consumption Volume of Anti-Migraine Drugs in Europe by Types



- 3.1.2 Revenue of Anti-Migraine Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Germany
 - 3.2.2 Market Status by Types in United Kingdom
 - 3.2.3 Market Status by Types in France
 - 3.2.4 Market Status by Types in Italy
 - 3.2.5 Market Status by Types in Spain
- 3.2.6 Market Status by Types in Benelux
- 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Anti-Migraine Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Anti-Migraine Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Germany
- 4.2.2 Demand Volume of Anti-Migraine Drugs by Downstream Industry in United Kingdom
 - 4.2.3 Demand Volume of Anti-Migraine Drugs by Downstream Industry in France
- 4.2.4 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Italy
- 4.2.5 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Spain
- 4.2.6 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Benelux
- 4.2.7 Demand Volume of Anti-Migraine Drugs by Downstream Industry in Russia
- 4.3 Market Forecast of Anti-Migraine Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-MIGRAINE DRUGS

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Anti-Migraine Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTI-MIGRAINE DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

- 6.1 Sales Volume of Anti-Migraine Drugs in Europe by Major Players
- 6.2 Revenue of Anti-Migraine Drugs in Europe by Major Players
- 6.3 Basic Information of Anti-Migraine Drugs by Major Players
- 6.3.1 Headquarters Location and Established Time of Anti-Migraine Drugs Major Players



- 6.3.2 Employees and Revenue Level of Anti-Migraine Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 ANTI-MIGRAINE DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Eli Lilly
 - 7.1.1 Company profile
 - 7.1.2 Representative Anti-Migraine Drugs Product
 - 7.1.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.2 Abbott Laboratories
 - 7.2.1 Company profile
 - 7.2.2 Representative Anti-Migraine Drugs Product
- 7.2.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 7.3 Eisai
 - 7.3.1 Company profile
 - 7.3.2 Representative Anti-Migraine Drugs Product
- 7.3.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Eisai
- 7.4 Allergan
 - 7.4.1 Company profile
 - 7.4.2 Representative Anti-Migraine Drugs Product
 - 7.4.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Allergan
- 7.5 Endo
 - 7.5.1 Company profile
 - 7.5.2 Representative Anti-Migraine Drugs Product
- 7.5.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Endo
- 7.6 GlaxoSmithKline
 - 7.6.1 Company profile
 - 7.6.2 Representative Anti-Migraine Drugs Product
- 7.6.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.7 Impax Laboratories
 - 7.7.1 Company profile
 - 7.7.2 Representative Anti-Migraine Drugs Product
 - 7.7.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Impax



Laboratories

- 7.8 Pfizer
 - 7.8.1 Company profile
 - 7.8.2 Representative Anti-Migraine Drugs Product
 - 7.8.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.9 AstraZeneca
 - 7.9.1 Company profile
 - 7.9.2 Representative Anti-Migraine Drugs Product
 - 7.9.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.10 Bayer
 - 7.10.1 Company profile
 - 7.10.2 Representative Anti-Migraine Drugs Product
 - 7.10.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Bayer
- 7.11 Johnson & Johnson
 - 7.11.1 Company profile
 - 7.11.2 Representative Anti-Migraine Drugs Product
- 7.11.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.12 Merck
 - 7.12.1 Company profile
 - 7.12.2 Representative Anti-Migraine Drugs Product
- 7.12.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.13 Teva
 - 7.13.1 Company profile
 - 7.13.2 Representative Anti-Migraine Drugs Product
 - 7.13.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Teva
- 7.14 Allergan
 - 7.14.1 Company profile
 - 7.14.2 Representative Anti-Migraine Drugs Product
 - 7.14.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Allergan
- 7.15 Amgen
 - 7.15.1 Company profile
 - 7.15.2 Representative Anti-Migraine Drugs Product
 - 7.15.3 Anti-Migraine Drugs Sales, Revenue, Price and Gross Margin of Amgen

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-MIGRAINE DRUGS

8.1 Industry Chain of Anti-Migraine Drugs



- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-MIGRAINE DRUGS

- 9.1 Cost Structure Analysis of Anti-Migraine Drugs
- 9.2 Raw Materials Cost Analysis of Anti-Migraine Drugs
- 9.3 Labor Cost Analysis of Anti-Migraine Drugs
- 9.4 Manufacturing Expenses Analysis of Anti-Migraine Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-MIGRAINE DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Anti-Migraine Drugs-Europe Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/A126625ADE8EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A126625ADE8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms